menu
    • menu

    Company profile for Hepagene Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hepagene Therapeutics, Inc. a clinical stage drug discovery and development company, devotes its effort towards discovering, developing and delivering innovative medicines that help patients prevail over liver diseases and other life-threatening diseases, especially non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection (HBV) and Hepatocellular Carcinoma (HCC).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hepagene TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    4560 Jin Ke Road, Building 1, 5th Floor Pudong District, Shanghai 201210
    Telephone
    Telephone
    021-61215841
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.hepagene.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hepagene Announces FDA Clearance of IND for HPG7233 THR Beta Agonist
    Hepagene Announces FDA Clearance of IND for HPG7233 THR Beta Agonist

    20 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hepagene-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-ind-for-hpg7233-thr-beta-agonist-301933223.html

    PR NEWSWIRE
    20 Sep 2023
    Share Share
    Hepagene Therapeutics to Present at the EASL Congress 2023
    Hepagene Therapeutics to Present at the EASL Congress 2023

    25 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hepagene-therapeutics-to-present-at-the-european-association-for-the-study-of-the-liver-easl-congress-2023-301834650.html

    PR NEWSWIRE
    25 May 2023
    Share Share
    Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
    Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH

    02 Dec 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/hepagene-therapeutics-initiates-the-rise-study-a-phase-iia-clinical-trial-of-hpg1860-in-patients-with-nash-1641805439.pdf

    PRESS RELEASE
    02 Dec 2021
    Share Share
    Hepagene Initiates the RISE Study, of HPG1860 in Patients with NASH
    Hepagene Initiates the RISE Study, of HPG1860 in Patients with NASH

    02 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/hepagene-therapeutics-initiates-the-rise-study-a-phase-iia-clinical-trial-of-hpg1860-in-patients-with-nash-301434639.html

    PRNEWSWIRE
    02 Dec 2021
    Share Share
    Hepagene Therapeutics Announces Positive Results from Phase I Trial of HPG1860
    Hepagene Therapeutics Announces Positive Results from Phase I Trial of HPG1860

    23 Aug 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/hepagene-therapeutics-inc-announces-positive-results-from-phase-i-trial-of-hpg1860-301359762.html

    PRNEWSWIRE
    23 Aug 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search